London-based IMU Biosciences Raises $53M Series A To Advance Immune System Profiling

The round was co-led by IQ Capital and Molten Ventures, with support from The British Business Bank, Meltwind, and existing investors.

Founded in 2019, IMU Biosciences is building one of the world’s largest immune datasets to transform how diseases are understood, diagnosed, and treated.

The company combines high-resolution immune profiling, multi-omics technologies, and AI-driven analytics to create detailed maps of the immune system from a simple blood sample.

Read Also - Spain-based Twinco Capital Secures €165Million In Series B Round

Its platform can analyse more than 100 million immune data points per sample, enabling researchers and clinicians to better understand disease mechanisms, monitor treatment responses, and identify personalised therapies.

To date, IMU Biosciences has raised approximately $60 million (£45 million). The latest funding will support the company's operational growth, expansion of its clinical platform and development of infrastructure needed to scale its immune profiling capabilities.

The investment will also help advance key clinical programmes, including stem cell transplant and solid organ transplant initiatives, as well as MANIFEST, a UK research consortium studying patient responses to cancer immunotherapies.

IMU Biosciences aims to establish a universal standard for immune profiling and accelerate the development of precision medicine by providing deeper insights into health and disease through advanced immune system analysis.

Dr John Baker, Chief Executive Officer of IMU Biosciences said: “We are delighted to announce IMU’s fundraise, which will allow us to expand our operations and develop our platform whilst continuing to deploy our groundbreaking technology across our clinical programmes as we work to fundamentally change how we understand, diagnose, and treat disease.

Despite the immune system’s profound importance on all aspects of our health, the system as a whole remains poorly understood – obscured by tools that are fragmented, mechanistic and low-resolution. With the largest immune system dataset globally and proprietary technology, IMU is uniquely positioned to fuel discoveries, devise treatments and empower clinicians; improving outcomes for patients across the full spectrum of human health and disease.”